• About Us
    • Our Company
    • Our People
  • Our Science
    • Our Science
    • Precise Antibody Engineering
    • Cytokine-Fusion Antibody
    • Novel T cell Targets
  • Pipeline
    • Pipeline
    • MMB101
    • MMB102
    • MFA011
  • Partnering
  • News
  • About Us
    • Our Company
    • Our People
  • Our Science
    • Our Science
    • Precise Antibody Engineering
    • Cytokine-Fusion Antibody
    • Novel T cell Targets
  • Pipeline
    • Pipeline
    • MMB101
    • MMB102
    • MFA011
  • Partnering
  • News

  • About us
    • Our Company
    • Our People
  • Contact
  • Home
  • Our Science
    • Cytokine-Fusion Antibody
    • Novel T cell Targets
    • Precise Antibody Engineering
  • Partnering with Us
  • Pipeline
    • MFA011
    • MMB101
    • MMB102

한글 Creating therapeutics to fight the most serious diseases

At MediMabBio, our focus is to engineer new protein therapeutics that modulate T cells – the master regulator of immune response. T cell dysfunctions are often the root cause of many diseases including cancer, where tumors develop sophisticated evasive mechanisms to avoid anti-tumor immune responses, and autoimmune diseases, where malfunctioning T cells contribute to hyperactivation of immune responses damaging normal, healthy tissues.

To overcome the limitations of conventional immunotherapeutics, our approach is centered on rational design: a dynamic process that harnesses the power of computational modeling, structural biology insights, and cutting-edge molecular engineering. This involves going beyond the conventional hit-based discovery methods, and we employ a rigorous workflow to predict and optimize the characteristics of our drug candidates. Our approach allows us to engineer protein therapeutics with unparalleled precision, ensuring enhanced specificity, potency, and safety profiles.

Precise Antibody Engineering

Engineering expertise specialized in antibody biology for the development of novel monoclonal antibodies that are designed to target novel epitopes for optimized interaction with their target receptors.

Cytokine-Antibody Fusion Protein

Develop innovative cytokine-antibody fusion protein that can overcome the limitations of off-target toxicities in traditional cytokine therapies by merging the potent properties of cytokines with targeted antibody delivery.

Novel T Cell Target

Design therapeutic strategies that can effectively target the distinct receptors expressed on the surfaces of CD4+ and CD8+ T cells by leveraging our understanding of T cell biology.

  • Home
  • Our Company
    • Our Company
    • Our People
  • Our Science
    • Our Science
    • Precise Antibody Engineering
    • Cytokine-Fusion Antibody
    • Novel T cell Targets
  • Pipeline
    • Pipeline
    • MMB101
    • MMB102
    • MFA011
  • Partnering with Us
  • News
  • Contact

#721, 54, Changeop-ro, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea, 13449 Tel. 82-(0)31-623-2100 Fax. 82-(0)31-751-2101 Email. info@medimabbio.com

©MEDIMABBIO. ALL RIGHTS RESERVED.